Technological and Scientific Prospection of Glycated Hemoglobin (HbA1c) Point-Of-Care Testing

• Autor(a) principal: Farrapo, Jéssica Silva Teles
• Data de Publicação: 2022
• Outros Autores: Gris, Eliana Fortes, Nascimento, Paulo Gustavo Barboni Dantas, Ferreira, Eduardo Antonio
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Cadernos de Prospecção (Online)
• Texto Completo: https://periodicos.ufba.br/index.php/nit/article/view/49263
• topic: Hemoglobina Glicada; HbA1c; Testes Imediatos.; Glycated Hemoglobin; HbA1c; Point-of-care Testing.

Glycated hemoglobin (HbA1c) is a biomarker used in the diagnosis and long-term evaluation of Diabetes mellitus. The development of HbA1c point-of-care testing allows simple analysis with immediate results, facilitating care. This study presents a technological and scientific prospection study based on the survey and analysis of patent documents and scientific paper of HbA1c point-of-care testing. The technological prospection revealed that China, United States and South Korea lead the technological production scenario and the North American company Polymer Technology Systems leads the deposits ranking. The patent survey shows that there is current technological interest in these point-of-care testing, justified by the increase in patent filings in recent years, peaking in 2019. The scientific prospection reveals that the United States leads the scientific production and points out that the market focus of these rapid tests are clinical laboratories, offices and specialized clinics, due to the speed and analytical simplicity.